Lyell Immunopharma (NASDAQ:LYEL) Insider Sells $39,084.69 in Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL) insider Gary Lee sold 1,671 shares of the firm’s stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total transaction of $39,084.69. Following the transaction, the insider directly owned 16,938 shares of the company’s stock, valued at $396,179.82. The trade was a 8.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Lyell Immunopharma Price Performance

NASDAQ LYEL traded up $1.04 on Thursday, reaching $25.38. The company had a trading volume of 63,758 shares, compared to its average volume of 86,064. The firm has a market cap of $539.07 million, a price-to-earnings ratio of -1.10 and a beta of -0.14. Lyell Immunopharma, Inc. has a fifty-two week low of $7.65 and a fifty-two week high of $45.00. The business has a 50 day moving average of $27.98 and a two-hundred day moving average of $19.64.

Lyell Immunopharma (NASDAQ:LYEL) last announced its earnings results on Wednesday, November 12th. The company reported ($2.13) EPS for the quarter, topping the consensus estimate of ($2.81) by $0.68. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.01 million. Lyell Immunopharma had a negative return on equity of 96.68% and a negative net margin of 794,292.69%. As a group, research analysts predict that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lyell Immunopharma

A number of hedge funds have recently added to or reduced their stakes in LYEL. BBR Partners LLC bought a new position in shares of Lyell Immunopharma during the 4th quarter worth approximately $210,000. Marshall Wace LLP acquired a new position in shares of Lyell Immunopharma during the 2nd quarter valued at $94,000. Jane Street Group LLC bought a new position in Lyell Immunopharma during the fourth quarter worth $382,000. Bridgeway Capital Management LLC acquired a new stake in Lyell Immunopharma in the second quarter worth $159,000. Finally, Clarius Group LLC grew its holdings in Lyell Immunopharma by 4.3% in the third quarter. Clarius Group LLC now owns 19,958 shares of the company’s stock worth $324,000 after purchasing an additional 820 shares during the period. 66.05% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Thursday, January 22nd. HC Wainwright upgraded shares of Lyell Immunopharma from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $20.00 to $45.00 in a research report on Tuesday, December 9th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $45.00.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.